Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
4.020
-0.050 (-1.23%)
At close: Sep 22, 2026, 4:00 PM EDT
4.030
+0.010 (0.25%)
After-hours: Sep 22, 2026, 7:30 PM EDT
Seres Therapeutics Employees
Seres Therapeutics had 66 employees as of December 31, 2025. The number of employees decreased by 37 or -35.92% compared to the previous year.
Employees
66
Change (1Y)
-37
Growth (1Y)
-35.92%
Revenue / Employee
$28,530
Profits / Employee
-$340,348
Market Cap
39.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66 | -37 | -35.92% |
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| aTyr Pharma | 60 |
| Actinium Pharmaceuticals | 27 |
| Veru Inc. | 20 |
| BriaCell Therapeutics | 16 |
| CervoMed | 15 |
MCRB News
- 7 days ago - Seres Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 14 days ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics files $300M mixed securities shelf - TheFly
- 5 weeks ago - Seres Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18) - TheFly
- 6 weeks ago - Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - GlobeNewsWire
- 6 weeks ago - Seres Therapeutics Earnings release: Q2 2026 - Filings